Syndax Pharmaceuticals, Inc. (SNDX)
SNDXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$9.53
-0.0300 (-0.31%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $859.40m
- P/E
- –
- EPS, last 4 quarters
- $-2.36
- Dividend yield
- –
- Day range
- –
- 52-week range
- $9.22 to $25.59
- Average volume
- 2.62m
- Previous close
- $9.56
Analysts
7 coveringBuy6 buy, 1 hold, 0 sell
Targets a year out average $37.38, +292.2% from here
Earnings
next estimate $-0.5200Next report
Dec 2025
-21.9%
Mar 2026
+18.6%
Jun 2026
-22.2%
Sep 2026
-5.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $68.73m | $64.86m | $72.79m | $83.30m |
| Gross profit | $66.02m | $62.23m | $69.58m | $69.30m |
| Operating income | -$62.55m | -$34.20m | -$39.99m | -$41.90m |
| Net income | -$68.01m | -$42.67m | -$49.36m | -$49.43m |
Last four quarters: revenue $289.68m, margin -72.3%, free cash flow –
News
8 latest- Syndax Posts Q3 Loss Narrows As Revenue Jumps 82% On Revuforj, Niktimvo Growth RTTNews · 7 days ago
- Syndax (SNDX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 7 days ago
- What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings CallMarketBeat · Nov 2, 2026
- Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Beats Revenue EstimatesZacks · Nov 2, 2026
- Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to DeclineZacks · Oct 28, 2026
- Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks · Oct 26, 2026
- Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data RTTNews · Oct 16, 2026
- Stocks Finish Lower Ahead of Wednesday’s CPI ReportBarchart · Oct 14, 2026
The company
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- syndax.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.